The oncology therapeutics developer has added $66m to its coffers thanks to investors including Berkeley Catalyst Fund.

Flagship Pioneering has re-opened its Fund VII to raise an additional $2.23bn that brought the vehicle’s total capital to $3.37bn.

The Industrial Biotechnology Innovation Centre will invest in research projects at Scottish universities to support the creation of more spinouts.

Alexandria Venture Investments was among the participants in a series A for the cellular cancer therapeutics developer based on work at Institut Curie and Memorial Sloan Kettering.

Alexandria Venture Investments was among the participants in a series A round for the cellular cancer therapeutics developer.

Limited partners including Alexandria Venture Investments and Royal Bank of Canada backed the healthcare technology-focused firm's first fund.

11Street and CJ Group contributed to a $71.8m round for on-demand logistics provider Barogo while Eli Lilly helped provide $66m for macrocycle drug developer Circle Pharma.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Broad Institute and UPenn-linked cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

GV and Novo-backed cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.